A Canadian single-centre experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for abdominal malignancies

Background: Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has recently shown promise for the treatment of patients with various types of peritoneal carcinomatosis (PC). However, it is an extensive procedure that is associated with a variety of morbidities. We evaluated the safety and clinical outcomes of CRS-HIPEC performed at our centre.

Methods: Patients with abdominal malignancies who underwent CRS-HIPEC between February 2005 and December 2018 at the Centre hospitalier de l’Université de Montréal (CHUM) were retrospectively reviewed.

Results: A total of 141 patients were identified (66 with appendiceal cancer, 62 with colorectal cancer, 10 with mesothelioma and 3 with small intestinal tumours). The median age was 55 years. Median overall survival (OS) was not reached for patients with appendiceal tumours; it was 38.3 months for colorectal cancers. Among patients with colorectal cancer, survival was significantly better for those who received intraperitoneal HIPEC with oxaliplatin (74.9 mo) compared with mitomycin C (29.1 mo) ($p = 0.006$). Complete cytoreductive surgery and low peritoneal carcinomatosis index were associated with the highest overall survival in patients with appendiceal tumours and those with colorectal tumours.

Conclusion: CRS-HIPEC can be performed with acceptable morbidity in patients with PC. These results validate the outcomes of previously reported trials, but further prospective trials are warranted to determine which patients will most benefit from the addition of HIPEC to CRS.

Contexte : La chirurgie cytoréductrice associée à la chimiothérapie hyperthermique intrapéritonéale (CCR-CHIP) s’est récemment révélée prometteuse pour le traitement de divers types de carcinomatose péritonéale (CP). Il s’agit toutefois d’une chirurgie extensive qui est associée à diverses morbidités. Nous avons évalué l’innocuité et l’issue clinique des CCR-CHIP effectuées dans notre centre.

Méthodes : Les cas de cancers abdominaux traités par CCR-CHIP entre février 2005 et décembre 2018 au Centre hospitalier de l’Université de Montréal (CHUM) ont été passés en revue rétrospectivement.

Résultats : En tout, 141 patients ont été recensés (66 porteurs d’un cancer de l’appendice, 62 avec colorectal cancer, 10 avec mésothéliome et 3 de tumeurs du grêle). L’âge médian était de 55 ans. La survie globale (SG) médiane n’a pas été atteinte chez les patients présentant des tumeurs de l’appendice; elle a été de 38,3 mois dans les cas de cancer colorectal. Parmi les patients atteints de cancer colorectal, la survie a été significativement meilleure chez ceux qui ont été traités par CHIP avec oxaliplatine (74,9 mois) plutôt que mitomycine C (29,1 mois) ($p = 0,006$). La chirurgie cytoréductrice complète et un index de carcinomatose péritonéale faible ont été associés à la meilleure survie chez les patients atteints de tumeurs de l’appendice et de tumeurs colorectales.

Conclusion : La CCR-CHIP s’accompagne d’une morbidité acceptable chez les patients atteints de CP. Ces résultats valident les conclusions de rapports précédents, mais il faudra mener des études prospectives plus approfondies pour déterminer quels patients bénéficieront le plus de l’ajout de la CHIP à la CR.
**Methods**

This was a retrospective analysis approved by the research ethics board of the Centre hospitalier de l’Université de Montréal. All patients with abdominal neoplasms with peritoneal involvement who underwent CRS-HIPEC between February 2005 and December 2018 at our centre were recorded. Patients with appendiceal tumours, mesotheliomas and PC secondary to colorectal and small bowel adenocarcinomas were included. Patients with ovarian and gynecologic neoplasia were excluded. Data on age, date of diagnosis, synchronous or metachronous tumours, body surface area, perioperative chemotherapy, pathology, postoperative complications, duration of intensive care unit stay, duration of total hospital stay, transfusions and dates of recurrence and death were collected. Our study focused on appendiceal and colorectal cancers; thus, mesotheliomas and small bowel tumours were excluded from the survival analysis.

Eligible patients had cytoreductive surgery as first described by Sugarbaker. After complete cytoreduction, HIPEC was administered. In most cases, patients received either mitomycin C over 90 minutes or oxaliplatin over 30 minutes, after the drug was heated to 40°C–42°C. The chemotherapy agent was selected according to the type of disease, the patient’s previous exposure to chemotherapy and the performance status of the patient.

The PCI score was determined intraoperatively by the surgeon, along with the completeness of cytoreduction (CC) score. CC-0 indicates that no macroscopic residual cancer remained, CC-1 indicates that no nodule larger than 2.5 mm in diameter remained and CC-2 indicates that nodules between 2.5 mm and 2.5 cm in diameter remained. PCI scores range from 1 to 39. Postoperative complications were recorded according to the common terminology criteria for adverse events, version 5. Comprehensive Complication Index (CCI) score was calculated using a downloaded calculator. This recently studied index is highly sensitive as it represents the sum of all complications, each weighted by its severity.

Descriptive statistics were used. We calculated p values for differences between types of intra-abdominal chemotherapy using χ² tests. DFS, progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier curves plotted with GraphPad Prism 7. Statistical significance was defined as p < 0.05, obtained by a 2-tailed test.

**Results**

Of the 141 patients who underwent CRS-HIPEC between February 2005 and December 2018, 58 were male and 83 were female, with a median age of 55 years (range 15–77 yr). In total, 46.8% (66 patients) of the tumours were neoplasms of the appendix and 44.0% (62 patients)
were colorectal cancers (Figure 1). In appendiceal tumours, 39.4% (26/66) of the cases were DPAM while 56.1% (37/66) were PMCA. Excluding those with mesothelioma, 90 patients (68.7%) had synchronous disease.

**Surgical outcomes**

At the time of cytoreductive surgery, 22.0% of patients underwent splenectomies and 23.4% had resection of liver metastasis, with a mean of 1 bowel anastomosis per operation (Table 1). Blood transfusion was required in 36 cases with an average hospital admission of 16.75 days, including stays in the intensive care unit if required. The most common complications were gastrointestinal, including ileus, and the mean CCI score was 17.7. No 30-day mortality was observed. Two patients experienced anastomotic leak. Complete cytoreduction (CC-0) was achieved in 89 patients (63.1%), with an average PCI score of 15.

**Chemotherapy**

Systemic neoadjuvant chemotherapy was administered to 77 of the 141 patients (54.6%). Neoadjuvant chemotherapy was administered mainly to patients with colorectal cancers (both synchronous and metachronous metastases). Among patients with PMCA, it was predominately given for synchronous tumours. Only 3 patients with DPAM received neoadjuvant systemic chemotherapy. Hyperthermic intraperitoneal injection of oxaliplatin was used for 60 patients and mitomycin C was used for 72 patients (Table 2). Intrabdominal use of mitomycin C was predominant among patients with appendiceal tumours and oxaliplatin use was more common among patients with colorectal cancers ($p = 0.05$). Among patients with colorectal cancers, intrabdominal oxaliplatin use was significantly higher in those with synchronous tumours ($p = 0.019$).

**Survival outcomes**

**Appendiceal tumours**

The median DFS for patients with DPAM was 149.8 months; median OS was not reached (Figure 2). Among patients with PMCA, median DFS and OS were not reached (Figure 3). Estimated 10-year survival rates of DPAM and PMCA were 89% and 75%, respectively.

| Table 1. Clinical and operative characteristics of patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
|---------------------------------|------------------|
| Characteristic                  | No. (% of patients) |
| Procedure                       |                   |
| Splenectomy                     | 31 (22.0)         |
| Hepatic resection               | 33 (23.4)         |
| Peritonectomy                   | 120 (85.1)        |
| Right diaphragm resection       | 62 (43.9)         |
| Left diaphragm resection        | 32 (22.6)         |
| Glisson capsulectomy            | 44 (31.2)         |
| Cholecystectomy                 | 14 (9.9)          |
| Partial gastrectomy             | 9 (6.3)           |
| Lesser omentum resection        | 11 (7.8)          |
| Partial pancreatectomy          | 7 (4.9)           |
| Small bowel resection           | 61 (43.2)         |
| Right hemicolecotmy             | 53 (37.5)         |
| Left hemicolecotmy              | 42 (29.7)         |
| Resection of rectum             | 21 (14.8)         |
| Hysterectomy in females         | 32/83 (38.5)      |
| BSO in females                  | 47/83 (56.6)      |
| Partial cystectomy              | 5 (3.5)           |
| Bowel anastomosis               | 75 (53)           |
| No. of bowel anastomoses per patient, mean (range) | 1 (0–3) |
| Anastomosis leak                | 2                 |
| Duration of surgery, h, mean (range) | 8.9 (2.5–17.5) |
| Blood loss, mL, mean (range)    | 548 (15–3000)     |
| Blood transfusion               | 36 (25.5)         |
| Duration of ICU stay, d, mean (range) | 1.5 (0–33) |
| Duration of hospital admission, d, mean (range) | 16.75 (5–184) |
| CCI score, mean (range)         | 17.7 (8–50.1)     |
| PCI score, mean (range)         | 15 (1–39)         |
| Completeness of cytoreduction   |                   |
| CC-0                            | 89                |
| CC-1                            | 28                |
| CC-2                            | 7                 |
| Unspecified                     | 16                |

BSO = bilateral salpingo-oophorectomy; CC-0 = no macroscopic residual cancer remained; CC-1 = no nodule > 2.5 mm in diameter remained; CC-2 = nodules between 2.5 mm and 2.5 cm in diameter remained; CCI = Comprehensive Complication Index; ICU = intensive care unit; PCI = peritoneal cancer index.

*Unless indicated otherwise.
In patients with PMCA, intraperitoneal HIPEC with oxaliplatin showed a trend toward better DFS and OS, although this was not statistically significant, when compared with intra-abdominal use of mitomycin C ($p = 0.28$ for DFS and $p = 0.33$ for OS). The median DFS for the mitomycin C group was 37.1 months; it was not possible to calculate it for the oxaliplatin group. The median OS was not reached for either chemotherapy group ($p = 0.55$; Figure 4A and 4B). The same trend toward better OS was also seen in patients with synchronous PMCA tumours ($p = 0.33$; Figure 4C); the median OS was not reached for these patients.

Completeness of cytoreduction and PCI score were found to be prognostic factors and predictive of better survival. Although the median OS was not reached in patients with PMCA who underwent complete (CC-0) or incomplete resection (CC-1 and CC-2), complete resection was associated with better survival ($p = 0.08$; Figure 5A). Lower PCI scores were also associated with better survival. The median OS was not reached in patients with PMCA and PCI scores of 1–20 whereas the median OS was 78.7 months for those with PCI scores of 21–39 ($p < 0.001$; Figure 5C).

**Table 2. Characteristics of patients according to type of intra-abdominal chemotherapy**

| Characteristic          | Mitomycin C | Oxaliplatin |
|-------------------------|-------------|-------------|
|                         | $n = 72$    | $n = 60$    |
| Appendiceal tumours     | 40          | 25          |
| Colorectal tumours      | 27          | 34          |
| Appendiceal tumours     | 17          | 9           |
| DPAM                    | 22          | 14          |
| Unspecified             | 1           | 2           |
| Small intestine tumours | 2           | 1           |
| Mesothelioma            | 3           | 0           |

**Fig. 2.** Kaplan—Meier curves for (A) disease-free survival and (B) overall survival among patients with disseminated peritoneal adenomucinosis who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

**Fig. 3.** Kaplan—Meier curves for (A) disease-free survival and (B) overall survival among patients with colorectal and peritoneal mucinous carcinomatosis (PMCA) who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

In patients with PMCA, intraperitoneal HIPEC with oxaliplatin showed a trend toward better DFS and OS, although this was not statistically significant, when compared with intra-abdominal use of mitomycin C ($p = 0.28$ for DFS and $p = 0.33$ for OS). The median DFS for the mitomycin C group was 37.1 months; it was not possible to calculate it for the oxaliplatin group. The median OS was not reached for either chemotherapy group ($p = 0.55$; Figure 4A and 4B). The same trend toward better OS was also seen in patients with synchronous PMCA tumours ($p = 0.33$; Figure 4C); the median OS was not reached for these patients.

Completeness of cytoreduction and PCI score were found to be prognostic factors and predictive of better survival. Although the median OS was not reached in patients with PMCA who underwent complete (CC-0) or incomplete resection (CC-1 and CC-2), complete resection was associated with better survival ($p = 0.08$; Figure 5A). Lower PCI scores were also associated with better survival. The median OS was not reached in patients with PMCA and PCI scores of 1–20 whereas the median OS was 78.7 months for those with PCI scores of 21–39 ($p < 0.001$; Figure 5C).
Colorectal tumours

Patients with colorectal tumours with PC had a worse prognosis than those with PMCA; the median DFS and OS were 13 and 38.3 months, respectively ($p < 0.001$ for both comparisons) (Figure 3). The estimated 5-year survival rate was 42%.

Intraperitoneal HIPEC with oxaliplatin was associated with better survival. The median DFS for patients who received oxaliplatin was 15.7 months, compared with 9 months for those who received mitomycin C ($p = 0.017$; Figure 6A). Median OS was 74.9 and 29.1 months for patients who received oxaliplatin and mitomycin C, respectively ($p = 0.006$; Figure 6B). The significant improvement in OS with intra-abdominal use of oxaliplatin was still observed in both synchronous and metachronous colorectal tumours. The median OS was not reached in patients with synchronous tumours who received HIPEC with oxaliplatin; it was 29.1 months in these patients who received mitomycin C ($p = 0.015$). OS was 74.9 months for patients with metachronous tumours who received oxaliplatin and 31 months for those who received mitomycin C ($p = 0.022$) (Figure 6C and 6D).

Complete cytoreduction and lower PCI score were associated with better survival in patients with colorectal cancers. The median OS was 41.7 and 31.0 months for patients who underwent complete and incomplete cytoreductive surgery, respectively ($p = 0.02$; Figure 5B). Patients who had a PCI score less than 11 had better survival than those with a score of 11–15 or more than 15 (75.4 mo v. 32.6 mo v. 28.1 mo; $p = 0.002$) (Figure 5D). Although this finding was not statistically significant, left-sided colorectal tumours were associated with better survival than right-sided tumours; median OS was 41.7 versus 35.6 months ($p = 0.94$; Figure 7).

**Discussion**

Peritoneal carcinomatosis was once considered a terminal disease and treated with only palliative systemic therapies. It carried a poor prognosis with a maximum reported median OS of 15 months. Later, PC was considered a regional form of metastasis that warranted local aggressive therapies in selected patients. Surgical resection, defined initially by Sugarbaker as cytoreductive surgery, and HIPEC were hence further developed.

CRS is a long procedure, with potential multiorgan resections and bowel anastomosis. It is associated with a high risk of intraoperative blood loss and morbidities. In our centre, mean intraoperative blood loss was merely 548 mL, and blood transfusion was needed in only 25.5% of patients. Our patients had a mean hospital stay of 16.75 days, and the mean CCI score was low. The morbidity profile of our patients was comparable to that of patients at other centres. Our centre is considered a reference centre in the province of Quebec, Canada.
the services of a large, dedicated, experienced surgical team, together with early intervention by all needed specialists, led to a low complication rate. Initially, all patients were admitted for observation to the intensive care unit (ICU), but lately patients have been admitted to the ICU only as indicated.

To our knowledge, there have been no prospective randomized controlled trials studying the benefit of neoadjuvant chemotherapy in PC of both colorectal and appendiceal tumours. However, studies have shown that perioperative chemotherapy for resectable liver metastasis of colorectal origin did not improve overall survival. In our cohort, liver metastases were mainly capsular lesions. Systemic chemotherapy was offered to reduce tumour size, which could improve outcomes and allow for easier and more complete resection, organ preservation and less morbidity. Neoadjuvant chemotherapy was offered to only 54.6% of our patients, who had mainly colorectal and PMCA cancers. Preoperative systemic chemotherapy was offered to a few patients with DPAM, because the waiting time to surgery is long in Quebec and according to our local experience some patients did have a response. A retrospective study of 34 patients with PMCA showed a short-term survival benefit in patients with complete response only. Thus, systemic neoadjuvant chemotherapy is offered for better surgical feasibility, not for survival benefit. Future randomized controlled trials are warranted to clarify the indications of neoadjuvant therapy in this setting.

In our study, HIPEC with oxaliplatin was associated with better DFS and OS in patients with colorectal cancer when compared with the use of mitomycin C, but the difference was not statistically significant in patients with PMCA. Leung and colleagues, in a retrospective analysis of 201 patients, showed that use of intraperitoneal oxaliplatin for PC of colorectal adenocarcinomas was associated with better survival outcomes, particularly in patients with...
non–signet cell tumours.27 On the other hand, the American Society of Peritoneal Surface Malignancies (ASPSM) demonstrated that use of mitomycin C was associated with slightly better OS (a finding that was not statistically significant), but in subgroup analysis, the use of mitomycin C improved survival in patients with low burden disease who had complete resection.28 A propensity score matched analysis confirmed that hyperthermic oxaliplatin use during HIPEC did not increase morbidities or mortalities.29,30

Thus, the choice of intraperitoneal chemotherapy may vary according to several factors, including histology subtypes (grade of tumour and presence or absence of signet cells), disease burden and patients’ response to exposure to oxaliplatin in previous systemic therapy. It should be noted that in the PRODIGE 7 study, a randomized controlled trial of 265 patients with PC secondary to colorectal tumours, HIPEC with oxaliplatin did not improve survival when compared with CRS only. This trial is the only randomized controlled one present in the literature.9 In our centre, intraperitoneal mitomycin C in appendiceal tumours is usually used to allow longer exposure of the peritoneum to the chemotherapy, as prolonged peritoneal oxaliplatin use is associated with increased risk of peritoneal bleeding. On the other hand, mitomycin C is used for HIPEC for patients with PC of colorectal origin whose disease is resistant or has progressed after systemic oxaliplatin therapy. Thus, with these strategies, mitomycin C is used for patients whose disease is already associated with a worse prognosis, which can explain the survival results we obtained.

In our cohort, patients with appendiceal tumours had prolonged survival with CRS and HIPEC, with an estimated 10-year survival rate of 89% and 75% for DPAM and PMCA subtypes, respectively. These results were slightly higher than those reported by Chua and colleagues in a retrospective study, where patients with appendiceal mucinous neoplasms and peritoneal involvement had a median OS of 16.3 years, with 10- and 15-year survival rates of 63% and 59%, respectively.31 On

Fig. 6. Kaplan–Meier curves of (A) disease-free survival and (B) overall survival among patients with colorectal cancer, and Kaplan–Meier curves of overall survival in patients with (A) synchronous tumour and (D) metachronous tumours, according to the type of intraperitoneal chemotherapy used.
the other hand, patients with colorectal cancer in our cohort had a median OS of 38.3 months and a 5-year survival rate of 42%. This was similar to the results of most published studies, in which median OS ranged between 32 and 41 months.32–34

Completeness of cytoreduction and PCI score are considered important prognostic factors, as patients with CC-0 and a low PCI score had the highest survival rate for both appendiceal and colorectal tumours. In patients with colorectal tumours, complete cytoreduction was associated with better survival than incomplete cytoreduction, with a median OS of 41.7 months, which is similar to the survival results in the PRODIGE 7 study. 9,10 In that trial, all patients received intra-abdominal oxaliplatin infusion and only patients with a PCI score less than 25 were included. In contrast, in our study, mitomycin C was used in cases of oxaliplatin resistance. In the PRODIGE 7 study, patients with PCI scores less than 11 had the highest survival, but subgroup analysis showed that patients with PCI scores of 11–15 benefited the most from HIPEC. The correlation between PCI and survival was also obvious in our study, but we lacked a comparative group of patients treated with CRS without HIPEC. In another retrospective study, Elias and colleagues showed that patients with PCI scores less than 19 had better survival than those with PCI scores higher than 19.13

Similar results were observed in appendiceal tumours in our study, as patients with PCI scores less than 20 had much better survival than those with PCI scores of 20 and more. Jimenez and colleagues cited PCI as a prognostic factor in a retrospective study of 387 patients, in which patients with PCI scores less than 20 had 5-year OS of 100% and 60% in DPAM and PMCA, respectively; these were significantly different than the results for patients with PCI greater than 20.16

Sidedness of the primary tumour in colorectal cancer plays an important role in prognosis in some series. Rightsided tumours are associated with worse survival than leftsided tumours.37,38

We performed resection of hepatic and subcapsular lesions in 23% of our patients. The presence of liver metastases was initially considered a contraindication to CRS and HIPEC. Later, a curative approach was considered in patients with a limited number of liver metastases.39 In a French retrospective analysis of 43 patients who underwent CRS and HIPEC for peritoneal carcinomatosis of colorectal origin, there was no difference in survival between patients with or without liver metastases.40 A recent meta-analysis of retrospective studies showed that patients with isolated PC experienced better survival than patients with both PC and liver metastases undergoing CRS and HIPEC, but the survival of patients in the latter group was still better than that of patients who underwent systemic chemotherapy alone.2,41,42 Therefore, a curative approach should still be considered in selected patients with both hepatic and peritoneal metastases.

**Limitations**

Our study has several limitations. It was a retrospective study with a limited number of patients and thus it is not ideal to draw conclusions for daily clinical practice. Some of the long-term complications may not have been fully reported, as some patients were followed in different outside clinics after discharge and thus we sometimes lacked detailed follow-up data. Moreover, our surgeons may have created a highly selected patient population by performing CRS and HIPEC only on well, fit patients. In addition, the study lacked a comparison group of patients who underwent CRS without HIPEC, and thus it is not possible to fully determine the indications for and benefits of adding HIPEC to CRS. Further prospective trials are warranted to establish these indications.

**Conclusion**

CRS-HIPEC is an acceptable, safe therapeutic treatment option for patients with PC. It is considered by many as the standard of care in patients with appendiceal tumours, and it is gaining more popularity in peritoneal carcinomatosis secondary to colorectal tumours and other abdominal malignancies. To date, there exists no high-level evidence that clearly shows a benefit of the addition of HIPEC to CRS. Yet criteria for selecting the patients that will benefit the most from this procedure are variable, and the criteria for selecting patients for the addition of HIPEC are not well established. Further prospective randomized clinical trials are warranted for this population.
Affiliations: Department of Hematology-Oncology, Centre hospitalier de l’Université de Montréal, Montréal, Que. (Nassabein, Aubin, Ayoub, Tehfé); and the Department of Surgery, Centre hospitalier de l’Université de Montréal, Montréal, Que. (Younan, Loungrarth, Mercier, Dagbert).

Competing interests: F. Mercier has received grants and personal fees from Ipsen and personal fees from Advanced Accelerator Applications.

Contributors: R. Younan and M. Tehfé designed the study. R. Nassabein, R. Loungrarth, F. Mercier, F. Dagbert, F. Aubin and J.-P. Ayoub acquired the data, which R. Nassabein, R. Younan and F. Dagbert analyzed. R. Nassabein and R. Younan wrote the article, which R. Younan, R. Loungrarth, F. Mercier, F. Dagbert, F. Aubin, J.-P. Ayoub and M. Tehfé critically revised. All authors gave final approval of the version to be published.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. de Cuba EM, Kwakman R, Knol DL, et al. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev 2013;39:121-7.
3. Ceelem WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 2010;7:108-15.
4. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012;30:263-7.
5. Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol 2012;38:617-23.
6. Sugarbaker PH. Epithelial appendiceal neoplasms. Cancer J 2009;15:225-35.
7. Sugarbaker PH. Peritoneectomy procedures. Ann Surg 1995;221:29-42.
8. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapeutic and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-43.
9. Quéné F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODICE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2012;13:266-76.
10. Quené F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODICE 7. J Clin Oncol 2018;36:256-66.
11. Simkens GA, Rovers KP, Nienhuis SW, et al. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res 2017;9:259-66.
12. Shaib WL, Assi R, Shamseddine A, et al. Appendiceal mucinous neoplasms: diagnosis and management. Oncologist 2017;22:1107-16.
13. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998;41:75-80.
14. Carr NJ, Cecil TD, Mohamed F, et al. a consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol 2016;40:14-26.
15. Bradley RF, Stewart JH, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30:551-9.
16. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449-56.
17. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237-42.
18. Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012;10:49-57.
19. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Rev 1996;22:359-74.
20. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5.0. Bethesda (MD): National Cancer Institute; 2017. Available: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11. pdf (accessed 2019 May 15).
21. Slankamenac K, Graf R, Barkun J, et al. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg 2013;258:1-7.
22. Pamela K, Matthias Z, Reinhold KR, et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a single-center experience in Austria. J Gastrointest Surg 2018;22:884-93.
23. Kim WR, Hur H, Min BS, et al. Single center experience with hyperthermic intraperitoneal chemotherapy. Ann Colon Rectal 2017;33:16-22.
24. Gupta N, Asif S, Gandhi J, et al. Role of CRS and HIPEC in appendiceal and colorectal malignancies: Indian experience. Indian J Gastroenterol 2017;36:126-30.
25. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14:1208-15.
26. Bijelic L, Kumar AS, Stuart OA, et al. Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival. Gastrointest Res Pract 2012;2012:163284.
27. Leung V, Hsu YR, Liaw W, et al. Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol 2017;43:144-9.
28. Prada-Villaverde A, Esquivel J, Lowy AM, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol 2014;10;77:95-85.
29. Gremonoprez F, Gossy II, Ceelem W. Use of hyperthermia versus normothermia during intraperitoneal chemoperfusion with oxaliplatin for colorectal peritoneal carcinomatosis: a propensity score matched analysis. Eur J Surg Oncol 2019;45:366-70.
30. Glockzin G, von Breitenbuch P, Schlitt HJ, et al. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. *J Surg Oncol* 2013;107:574-8.

31. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *J Clin Oncol* 2012;30:2449-56.

32. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. *J Clin Oncol* 2009;27:63-8.

33. Glehen O, Kwaśniewski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. *J Clin Oncol* 2004;22:3284-92.

34. Quenet F, Goere D, Mehta SS, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. *Ann Surg* 2011;254:294-301.

35. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. *J Clin Oncol* 2010;28:63-8.

36. Jimenez W, Sardi A, Nieroda C, et al. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol* 2014;21:4218-25.

37. Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: s meta-analysis of first-line clinical trials. *Eur J Cancer* 2017;70:87-98.

38. Grassadonia A, Di Marino P, Ficorella C, et al. Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. *J Cancer* 2019;10:5926-34.

39. Thomassen I, van Gestel YR, Lemmens VE, et al. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. *Dis Colon Rectum* 2013;56:1373-80.

40. Kianmanesh R, Scaringi S, Sabate J-M, et al. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. *Ann Surg* 2007;245:597-603.

41. El-Nakeep S, Rashad N, Oweira H, et al. Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review. *Expert Rev Gastroenterol Hepatol* 2017;11:249-58.

42. Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. *Ann Surg* 2016;263:1102-11.